Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 7/20 | 0.33 |
| ▸ | ATR | Q13535 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tert-Butyl Formate SCHEMBL27774767 | 0.92 | RORC (0.30) | RORC | |
| SCHEMBL3327840 | 0.85 | HTR6 (0.36) | — | |
| SCHEMBL4194643 | 0.75 | HRH3 (0.38) | — | |
| Tert-Butyl Formate SCHEMBL27774776 | 0.66 | HTR6 (0.37) | RORC | |
| SCHEMBL3326426 | 0.66 | F2RL1 (0.36) | — | |
| Tert-Butyl Formate SCHEMBL27774782 | 0.64 | RORC (0.43) | RORCGPR119 | |
| SCHEMBL4206169 | 0.62 | HRH3 (0.40) | — | |
| SCHEMBL21382035 | 0.60 | PDE1C (0.44) | — | |
| SCHEMBL3331201 | 0.60 | HTR6 (0.51) | — | |
| Hydrochloric Acid SCHEMBL31638109 | 0.60 | PDE1C (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507469-B2 | Azetidin compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor | ABBOTT GMBH & CO. KG (DE) | 2013-08-13 | — | — | US | claimed |
| US-20100137280-A1 | AZETIDIN COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2010-06-03 | — | — | US | claimed |
| EP-2155724-A1 | AZETIDIN COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | Abbott GmbH & Co. KG (DE) | 2010-02-24 | — | — | EP | claimed |
| WO-2008116833-A1 | AZETIDIN COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2008-10-02 | — | — | WO | claimed |
| US-8507469-B2 | Azetidin compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor | ABBOTT GMBH & CO. KG (DE) | 2013-08-13 | — | — | US | disclosed |
| US-20100137280-A1 | AZETIDIN COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2010-06-03 | — | — | US | disclosed |
| EP-2155724-A1 | AZETIDIN COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | Abbott GmbH & Co. KG (DE) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008116833-A1 | AZETIDIN COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137280-A1 | AZETIDIN COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | HTR6, HTR4, HTR3C | RORC 637/4885ATR 3815/4885GPR119 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.